Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen - PubMed (original) (raw)
Clinical Trial
. 2003 Oct 15;188(8):1213-30.
doi: 10.1086/378356. Epub 2003 Oct 3.
Farshad Guirakhoo, Richard Nichols, Sutee Yoksan, Robert Schrader, Chris Murphy, Paul Blum, Stephen Woodward, Karen McCarthy, Danell Mathis, Casey Johnson, Philip Bedford
Affiliations
- PMID: 14551893
- DOI: 10.1086/378356
Clinical Trial
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen
Thomas P Monath et al. J Infect Dis. 2003.
Abstract
ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis, using yellow fever (YF) 17D vaccine as a vector. In a double-blind phase 2 trial, 99 adults received vaccine, placebo, or YF 17D vaccine (YF-VAX). ChimeriVax-JE was well tolerated, with no differences in adverse events between treatment groups. Viremias resulting from administration of ChimeriVax-JE and YF-VAX were of short duration and low titer; 82 (94%) of 87 subjects administered graded doses (1.8-5.8 log(10)) of ChimeriVax-JE developed neutralizing antibodies. A second dose, administered 30 days later, had no booster effect. Previous inoculation with YF did not interfere with ChimeriVax-JE, but there was a suggestion (not statistically significant) that ChimeriVax-JE interfered with YF-VAX administered 30 days later. A separate study explored immunological memory both in subjects who had received ChimeriVax-JE 9 months before and in ChimeriVax-JE-naive subjects challenged with inactivated mouse-brain vaccine (JE-VAX). Anamnestic responses were observed in preimmune individuals. ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose.
Similar articles
- Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, Monath TP. Guirakhoo F, et al. Virology. 1999 May 10;257(2):363-72. doi: 10.1006/viro.1999.9695. Virology. 1999. PMID: 10329547 - Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F. Monath TP, et al. Vaccine. 1999 Apr 9;17(15-16):1869-82. doi: 10.1016/s0264-410x(98)00487-3. Vaccine. 1999. PMID: 10217584 - Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M. Nasveld PE, et al. Hum Vaccin. 2010 Nov;6(11):906-14. doi: 10.4161/hv.6.11.12854. Epub 2010 Nov 1. Hum Vaccin. 2010. PMID: 20864814 Free PMC article. Clinical Trial. - IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB, Vrati S. Appaiahgari MB, et al. Expert Rev Vaccines. 2010 Dec;9(12):1371-84. doi: 10.1586/erv.10.139. Expert Rev Vaccines. 2010. PMID: 21105774 Review. - A chimeric live attenuated vaccine against Japanese encephalitis.
Jones T. Jones T. Expert Rev Vaccines. 2004 Jun;3(3):243-8. doi: 10.1586/14760584.3.3.243. Expert Rev Vaccines. 2004. PMID: 15176941 Review.
Cited by
- Spectrum of disease outcomes in mice infected with YFV-17D.
Erickson AK, Pfeiffer JK. Erickson AK, et al. J Gen Virol. 2015 Jun;96(Pt 6):1328-1339. doi: 10.1099/vir.0.000075. Epub 2015 Feb 2. J Gen Virol. 2015. PMID: 25646269 Free PMC article. - Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T. Guirakhoo F, et al. J Virol. 2004 May;78(9):4761-75. doi: 10.1128/jvi.78.9.4761-4775.2004. J Virol. 2004. PMID: 15078958 Free PMC article. - Detection of yellow fever 17D genome in urine.
Domingo C, Yactayo S, Agbenu E, Demanou M, Schulz AR, Daskalow K, Niedrig M. Domingo C, et al. J Clin Microbiol. 2011 Feb;49(2):760-2. doi: 10.1128/JCM.01775-10. Epub 2010 Nov 24. J Clin Microbiol. 2011. PMID: 21106799 Free PMC article. No abstract available. - New vaccines for Japanese encephalitis.
Halstead SB, Thomas SJ. Halstead SB, et al. Curr Infect Dis Rep. 2010 May;12(3):174-80. doi: 10.1007/s11908-010-0098-z. Curr Infect Dis Rep. 2010. PMID: 21308526 - Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.
Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Vaccine. 2015. PMID: 25446819 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources